Burning Rock Biotech/$BNR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Burning Rock Biotech
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
Ticker
$BNR
Sector
Primary listing
Employees
667
Headquarters
Website
BNR Metrics
BasicAdvanced
$176m
-
-$0.77
1.50
-
Price and volume
Market cap
$176m
Beta
1.5
52-week high
$41.72
52-week low
$2.49
Average daily volume
22k
Financial strength
Current ratio
2.99
Quick ratio
2.684
Long term debt to equity
4.887
Total debt to equity
8.056
Interest coverage (TTM)
-1,828.17%
Profitability
EBITDA (TTM)
-4.885
Gross margin (TTM)
74.67%
Net profit margin (TTM)
-10.26%
Operating margin (TTM)
-10.16%
Effective tax rate (TTM)
-2.89%
Revenue per employee (TTM)
$119,110
Management effectiveness
Return on assets (TTM)
-4.02%
Return on equity (TTM)
-9.92%
Valuation
Price to revenue (TTM)
2.237
Price to book
0.33
Price to tangible book (TTM)
0.33
Price to free cash flow (TTM)
-43.063
Free cash flow yield (TTM)
-2.32%
Free cash flow per share (TTM)
-0.388
Growth
Revenue change (TTM)
4.60%
Earnings per share change (TTM)
-84.54%
3-year revenue growth (CAGR)
-1.42%
3-year earnings per share growth (CAGR)
-61.81%
What the Analysts think about BNR
Analyst ratings (Buy, Hold, Sell) for Burning Rock Biotech stock.
BNR Financial Performance
Revenues and expenses
BNR Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Burning Rock Biotech stock?
Burning Rock Biotech (BNR) has a market cap of $176M as of May 19, 2026.
What is the P/E ratio for Burning Rock Biotech stock?
The price to earnings (P/E) ratio for Burning Rock Biotech (BNR) stock is 0 as of May 19, 2026.
Does Burning Rock Biotech stock pay dividends?
No, Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders as of May 19, 2026.
When is the next Burning Rock Biotech dividend payment date?
Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders.
What is the beta indicator for Burning Rock Biotech?
Burning Rock Biotech (BNR) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.